Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to document the clinical and bacteriological efficacy of
retapamulin in the treatment of subjects with bacterial infections, including impetigo,
folliculitis, and minor soft tissue infections including secondarily infected eczema presumed
to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to
98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound
cultures will be collected, and then subjects will apply topical retapamulin twice daily for
five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus
aureus (MRSA) infection based on clinical presentation and physical exam, as well as
bacteriological efficacy based on culture results. It is anticipated that approximately 75
patients will be enrolled, with expectation that approximately 50 of these patients will have
MRSA infections.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston